医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Research and Markets: Community-Acquired Bacterial Pneumonia

2012年09月26日 AM01:59
このエントリーをはてなブックマークに追加


 

DUBLIN

Research and Markets (http://www.researchandmarkets.com/research/5fxhnt/communityacquired) has announced the addition of Decision Resources, Inc’s new report “Community-Acquired Bacterial Pneumonia” to their offering.

The community-acquired bacterial pneumonia (CABP) market is highly crowded and genericized; nevertheless, it has important unmet needs for new therapies that are active against key drug-resistant pathogens and that can demonstrate efficacy in the moderate to severe CABP population. Although the majority of CABP patients are treated in the outpatient setting, the inpatient setting represents more than half of the CABP market and will be the area of highest commercial growth over the 2010-2020 period. Key drivers of the CABP inpatient segment include the uptake of marketed and emerging antibiotic brands and the anticipated increase in disease severity among hospitalized patients.

Key Topics Covered:

– Executive Summary

– 1 Etiology and Pathophysiology

– 2 Epidemiology and Patient Populations

– 3 Current Therapies and Medical Practice

– 4 Unmet Needs

– 5 Emerging Therapies

– Overview

– Future Positioning of Key Competitors

– Drug Development and Regulatory Hurdles

– Oxazolidinones

– Overview

– Mechanism of Action

– Radezolid

– Macrolides and Related Agents

– Overview

– Mechanism of Action

– Solithromycin

– Quinolones

– Overview

– Mechanism of Action

– Nemonoxacin

– Delafloxacin

– JNJ-Q2

– Zabofloxacin

– Streptogramins

– Overview

– Mechanism of Action

– NXL-103

– 6 Market Outlook

– Appendix A Bibliography Community Acquired Bacterial Pneumonia

– Appendix B Market Forecast Methodology

– Appendix C Experts Interviewed Community Acquired Bacterial Pneumonia

– Tables and Figures

For more information visit http://www.researchandmarkets.com/research/5fxhnt/communityacquired

Source: Decision Resources, Inc

CONTACT

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare
and Medical Devices
, Pharmaceuticals

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Terns Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
  • Kyoto Semiconductor Announces a Photodiode in the Industry’s Smallest Class, with a Broad Range of Sensitivity Wavelengths, from 400 to 1,700 nm
  • 希少な重篤肺がんと診断された患者に対するファーストライン治療としての武田薬品のALUNBRIG®(ブリガチニブ)を米国FDAが承認
  • 美国FDA核准武田ALUNBRIG® (brigatinib)用作一种罕见严重类型肺癌患者的一线治疗选择
  • Firetinas: Is Your Telethermographic Scanner Accurate to Screen COVID-19?